Comparative Pharmacology
Head-to-head clinical analysis: ERYMAX versus WYAMYCIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYMAX versus WYAMYCIN S.
ERYMAX vs WYAMYCIN S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. It also acts as a motilin receptor agonist, stimulating gastrointestinal motility.
WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours.
WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults; prolonged to 4–6 hours in hepatic impairment; requires dosing adjustment in cirrhosis.
2-3 hours in normal renal function; prolonged to 24-48 hours in end-stage renal disease.
Renal excretion of unchanged drug: 10–15%; biliary/fecal excretion: 85–90% as active metabolites.
Renal (90-95% unchanged via glomerular filtration) and biliary (<5%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic